{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001727","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.228024+00:00","generated_at":"2026-05-27T14:28:37.210892+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study","bullets":["77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).","100% acute lesion success with conduction block; total PVI ablation time 11.6±4.5 minutes.","1 primary SAE (cardiac perforation) and 2 AEs (vertigo, creatinine elevation) all resolved.","Company on track to begin IDE study in 2025 for clinical validation.","Data presented at AF Symposium 2025; live case with 3D mapping on Abbott Ensite X System."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001727","json":"https://secwatch.observer/filing/0001437749-25-001727.json","markdown":"https://secwatch.observer/filing/0001437749-25-001727.md","text":"https://secwatch.observer/filing/0001437749-25-001727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/0001437749-25-001727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/plse20250121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:28:37.210892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}